GlassScriptPrepare for your visit
Judy Hamad
Dermatopathology (Dermatology) · Indianapolis, IN · NPI 1821624321
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$640.70
in general payments reported to CMS, 2019-2025
Who reported paying
General payments only, top 5 by amount.
- Janssen Biotech, INC. $241.90
- Dermavant Sciences, INC. $144.11
- Abbvie INC. $116.87
- Stemline Therapeutics INC. $107.10
- Genzyme Corporation $30.72
Drugs and devices associated with these payments
Tremfya Vtama Stelara
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Judy Hamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/11333241/judy-hamad